Miscellaneous
There are a range of different options for patients who require treatment escalation beyond dual or triple therapy, including premixed insulin, basa insulin plus mealtime insulin, and premixed GLP-1 RA and insulin. But how can we compare these different tactics, and going further, how do individual agents compare? Join Dr TIm Heise of the Profil Institute for an in-depth discussion of available trial data surrounding injectable therapies in type 2 diabetes. References Swinnen SG, et al. Cochrane Database Syst Rev. 2011; 2011(7):CD006383 Philis-Tsimikas A, et al. Diabetologia. 2020; 63(4):698-710 Bowering K, et al. Diabetes Care. 2017; 40(7):951-957 Klaff L, et al. Presented at ADA 2019; June 7-11, San Francisco, CA. Billings LK, et al. Diabetes Care. 2018; 41(5):1009-1016 Tabak AG, et al. Diabetes Ther. 2020;11(1):305-318.